---
layout: default
title: Acemetacin
parent: 僅模型預測 (L5)
nav_order: 15
evidence_level: L5
indication_count: 1
---

# Acemetacin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Acemetacin: From Inflammatory Pain Management to Osteoarthritis Susceptibility

## One-Sentence Summary

Acemetacin is a prodrug of indomethacin, belonging to the non-steroidal anti-inflammatory drug (NSAID) class, classically used to treat pain and inflammation in musculoskeletal conditions.
The TxGNN model predicts it may be effective for **Osteoarthritis Susceptibility**, with a high prediction score of **99.22%**.
However, **no clinical trials or published literature** were found to support this specific indication, placing this prediction at the earliest evidence stage (L5).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | NSAID for inflammatory pain (indomethacin prodrug; specific label indications unavailable) |
| Predicted New Indication | Osteoarthritis Susceptibility |
| TxGNN Prediction Score | 99.22% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Acemetacin is the glycolic acid ester prodrug of indomethacin. After oral administration, it is hydrolyzed by tissue esterases to release active indomethacin, which functions as a potent COX-1/COX-2 dual inhibitor. By blocking the arachidonic acid metabolic pathway, it suppresses the synthesis of prostaglandin E2 (PGE2), thereby reducing synovial inflammation and peripheral pain sensitization in joints.

The mechanistic link to osteoarthritis is biologically direct. Osteoarthritis pathology is driven by synovitis and cartilage degradation, both of which are mediated in part by prostaglandin-driven inflammatory cascades. COX inhibition targets this core pathway, and the parent compound indomethacin is already used clinically in osteoarthritis management globally. Acemetacin's prodrug design was specifically developed to reduce the gastrointestinal side effects of indomethacin while preserving its anti-inflammatory efficacy, making it mechanistically well-positioned for this indication.

That said, a critical note on data quality: the MOA field in this Evidence Pack is marked as unavailable, and the drug interaction database returned zero results — inconsistent with what is known about NSAIDs. These gaps indicate incomplete data ingestion, not an absence of known pharmacology. Any downstream decision must be based on externally verified pharmacological references rather than this dataset alone.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** The safety data fields (key warnings, contraindications, drug interactions) were not populated in this Evidence Pack. As an NSAID prodrug of indomethacin, acemetacin is expected to carry the full NSAID class-effect risk profile — including gastrointestinal ulceration, cardiovascular risk, renal impairment, and drug interactions with anticoagulants, diuretics, and other NSAIDs. These must be confirmed from the package insert before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model assigns a very high prediction score (99.22%), and the COX-1/COX-2 inhibition mechanism is pharmacologically well-suited to osteoarthritis. However, this is a pure model prediction (L5) with no supporting clinical trials or published literature for this specific indication, and the drug currently has no marketing authorization in Saudi Arabia.

**To proceed, the following is needed:**

- **Verify MOA and safety profile** from DrugBank API, EMA/FDA label, or published pharmacology references — the current dataset has blocking data gaps
- **Conduct a bridging literature search** for indomethacin (parent drug) in osteoarthritis as a mechanistic proxy, since the two compounds share the same active moiety
- **Search for acemetacin clinical use** in any inflammatory musculoskeletal indication (rheumatoid arthritis, ankylosing spondylitis, gout) to establish a clinical safety anchor
- **Assess regulatory pathway** — since the drug is not marketed in Saudi Arabia, determine whether a foreign approval (e.g., EU, Japan) exists as a reference basis
- **Define feasibility of evidence upgrade** — at minimum, identify whether an L3 observational or retrospective dataset exists before committing to prospective study design
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

